Secondhand smoke is an important modifiable risk factor in sickle cell disease: A review of the current literature and areas for future research
Repository Usage Stats
© 2016 by the authors; licensee MDPI, Basel, Switzerland.Sickle cell disease (SCD) is an autosomal recessive hemoglobinopathy that causes significant morbidity and mortality related to chronic hemolytic anemia, vaso-occlusion, and resultant end-organ damage. Tobacco smoke exposure (TSE) through secondhand smoke exposure in people with SCD of all ages and through primary smoking in adolescents and adults is associated with significantly increased morbidity, with increased rates of emergency department visits and hospitalizations for painful vaso-occlusive crises and acute chest syndrome (ACS). Secondhand smoke is also associated with pulmonary function abnormalities in children with SCD who are already at risk for pulmonary function abnormalities on the basis of SCD. TSE is emerging as one of the few modifiable risk factors of SCD. This review discusses the current state of the evidence with respect to TSE and SCD morbidity, discusses potential mechanisms, and highlights current gaps in the evidence and future research directions.
Published Version (Please cite this version)10.3390/ijerph13111131
Publication InfoCreary, SE; Eakin, MN; Kopp, BT; McGrath-Morrow, S; Sadreameli, SC; & Strouse, John J (2016). Secondhand smoke is an important modifiable risk factor in sickle cell disease: A review of the current literature and areas for future research. International Journal of Environmental Research and Public Health, 13(11). 10.3390/ijerph13111131. Retrieved from http://hdl.handle.net/10161/13333.
This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.
More InfoShow full item record
Associate Professor of Medicine
My research has focused on the epidemiology, risk factors, and prevention of the pulmonary and central nervous system complications of sickle cell disease and includes retrospective and prospective cohort studies and clinical trials. I received my Ph.D. in clinical investigation from the Johns Hopkins Bloomberg School of Public Health for a series of studies to identify predictors of cognitive function in children with sickle cell disease. This work has expanded to the evaluation